Emtricitabine/Tenofovir and Ledipasvir/Sofosbuvir Interaction

Understanding the Emtricitabine/Tenofovir and Ledipasvir/Sofosbuvir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Emtricitabine/Tenofovir belongs to the NRTI Combination (HIV PrEP) class and Ledipasvir/Sofosbuvir belongs to the NS5A/NS5B Inhibitor (HCV) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Using these drugs together can increase the amount of tenofovir that stays in your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Emtricitabine/Tenofovir has 9 total documented interactions on file in this dataset, and Ledipasvir/Sofosbuvir has 22. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your healthcare provider should watch you closely for any signs of side effects while you are on this combination. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Emtricitabine/Tenofovir or Ledipasvir/Sofosbuvir based on a web page, speak with your prescriber or pharmacist before making any change.